PLAU

Chr 10q22.2

plasminogen activator, urokinase

Aliases:: URK, UPA
MANE:: ENST00000372764.4

OMIM: 191840 ↗NCBI: 5328 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

PLAU · P00749

v62025-08-01

Predicted Aligned Error matrix for PLAU — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

82.1/ 100

Confident

431 residues

Confidence breakdown

Very high(≥ 90)54%
Confident(70–90)26%
Low(50–70)8%
Very low(< 50)12%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

Bleeding and platelet disorders
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Inherited bleeding disorders
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown

Disease associations (Open Targets)

Quebec platelet disorder
0.62
abdominal aortic aneurysm
0.50
myocardial infarction
0.49
inflammatory bowel disease
0.47
Recurrent thrombophlebitis
0.37
ischemic stroke
0.36
atherosclerosis
0.36
actinic keratosis
0.33
psoriasis vulgaris
0.32
diabetic foot
0.28

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Urokinase-type plasminogen activator

Serine protease that cleaves the inactive precursor plasminogen at a specific Arg-Val peptide bond, converting it into active plasmin (PubMed:1969415, PubMed:2521625, PubMed:4270330). Secreted as an inactive zymogen, it is recruited and activated at the cell surface through interaction with the urokinase plasminogen activator receptor (uPAR). Cell-surface activation enables localized, plasmin-dependent pericellular proteolysis, regulating extracellular matrix degradation in cell migration and tissue remodeling (PubMed:1829461, PubMed:2521625, PubMed:28849762). Also contributes to fibrinolysis and blood clot clearance by promoting plasmin generation (By similarity)